Gouws Capital LLC decreased its holdings in Xylem Inc. (NYSE:XYL - Free Report) by 43.5% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 11,966 shares of the industrial products company's stock after selling 9,225 shares during the period. Xylem makes up about 1.0% of Gouws Capital LLC's investment portfolio, making the stock its 22nd largest position. Gouws Capital LLC's holdings in Xylem were worth $1,388,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Heck Capital Advisors LLC purchased a new position in Xylem in the 4th quarter worth approximately $36,000. Pathway Financial Advisers LLC lifted its position in shares of Xylem by 122.4% during the fourth quarter. Pathway Financial Advisers LLC now owns 318 shares of the industrial products company's stock worth $37,000 after purchasing an additional 175 shares in the last quarter. SRS Capital Advisors Inc. boosted its stake in shares of Xylem by 69.5% in the fourth quarter. SRS Capital Advisors Inc. now owns 317 shares of the industrial products company's stock valued at $37,000 after purchasing an additional 130 shares during the period. Assetmark Inc. grew its holdings in Xylem by 3,887.5% during the 3rd quarter. Assetmark Inc. now owns 319 shares of the industrial products company's stock valued at $43,000 after purchasing an additional 311 shares in the last quarter. Finally, Versant Capital Management Inc increased its stake in Xylem by 318.2% during the 4th quarter. Versant Capital Management Inc now owns 368 shares of the industrial products company's stock worth $43,000 after buying an additional 280 shares during the period. 87.96% of the stock is owned by institutional investors and hedge funds.
Xylem Stock Performance
Shares of NYSE:XYL traded down $0.71 on Thursday, reaching $128.96. 1,494,560 shares of the company's stock were exchanged, compared to its average volume of 1,198,949. Xylem Inc. has a fifty-two week low of $113.26 and a fifty-two week high of $146.08. The business's 50-day moving average is $123.29 and its two-hundred day moving average is $127.10. The company has a quick ratio of 1.33, a current ratio of 1.76 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $31.33 billion, a price-to-earnings ratio of 35.23, a PEG ratio of 2.33 and a beta of 1.07.
Xylem (NYSE:XYL - Get Free Report) last issued its earnings results on Tuesday, February 4th. The industrial products company reported $1.18 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.12 by $0.06. Xylem had a net margin of 10.40% and a return on equity of 9.96%. The firm had revenue of $2.30 billion for the quarter, compared to analysts' expectations of $2.18 billion. During the same quarter last year, the company posted $0.99 earnings per share. Xylem's revenue was up 8.6% on a year-over-year basis. As a group, equities research analysts forecast that Xylem Inc. will post 4.65 EPS for the current year.
Xylem Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 19th. Investors of record on Tuesday, February 18th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $1.60 dividend on an annualized basis and a yield of 1.24%. This is a positive change from Xylem's previous quarterly dividend of $0.36. Xylem's payout ratio is currently 43.72%.
Analysts Set New Price Targets
Several analysts have recently weighed in on the company. Citigroup downgraded Xylem from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 5th. Robert W. Baird raised their price objective on Xylem from $139.00 to $148.00 and gave the company an "outperform" rating in a research note on Wednesday, February 5th. Wolfe Research reaffirmed a "peer perform" rating on shares of Xylem in a research report on Thursday, December 12th. Stifel Nicolaus dropped their price target on shares of Xylem from $166.00 to $150.00 and set a "buy" rating for the company in a research note on Friday, January 24th. Finally, TD Cowen cut their price target on shares of Xylem from $138.00 to $125.00 and set a "hold" rating on the stock in a report on Wednesday, November 6th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, Xylem has an average rating of "Moderate Buy" and a consensus price target of $149.90.
Read Our Latest Report on XYL
About Xylem
(
Free Report)
Xylem Inc, together with its subsidiaries, engages in the design, manufacture, and servicing of engineered products and solutions worldwide. It operates through four segments: Water Infrastructure, Applied Water, Measurement & Control Solutions, and Integrated Solutions and Services. The Water Infrastructure segment offers products, including water, storm water, and wastewater pumps; controls and systems; filtration, disinfection, and biological treatment equipment; and mobile dewatering equipment and rental services under the ADI, Flygt, Godwin, Sanitaire, Magneto, Neptune Benson, Ionpure, Leopold, Wedeco, and Xylem Vue brands.
Featured Stories

Before you consider Xylem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xylem wasn't on the list.
While Xylem currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.